ILC Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 4

ILC Therapeutics General Information

Description

Operator a biotechnology drug research platform intended for the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis and Psoriasis. The company's platform has been exploring the differences in immune response between the alpha-interferon sub-types with a view to identifying those that can be optimized in drug therapy, enabling health institutions and related medical centers with a drug therapy which can unlock the therapeutic potential of interferon and help in oncology treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Biocity
  • Bo'ness Road, Newhouse
  • Lanarkshire ML1 5UH
  • Scotland, United Kingdom
+44 07403 000000

ILC Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ILC Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Dec-2020 00.000 Completed Generating Revenue
6. Later Stage VC 29-Jun-2020 00000 00.000 00.000 Completed Generating Revenue
5. Accelerator/Incubator 15-Nov-2019 00.000 Completed Generating Revenue
4. Later Stage VC 09-Jul-2018 00000 00.000 00.000 Completed Generating Revenue
3. Later Stage VC 14-Dec-2017 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC 04-Jan-2017 $310K $700K 00.000 Completed Generating Revenue
1. Seed Round 30-Jul-2015 $390K $390K 00000 Completed Startup
To view ILC Therapeutics’s complete valuation and funding history, request access »

ILC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
A Ordinary 00,000 00.000000 00.00 00.00 00 00.00 000
Ordinary A 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary A 00,000 00.000000 00.0 00.0 00 00.0 00.000
Ordinary A 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary A 27,213 $1.251233 $11.04 $11.04 1x $11.04 8.76%
Ordinary A 5,555 $1.251233 $2.25 $2.25 1x $2.25 1.79%
To view ILC Therapeutics’s complete cap table history, request access »

ILC Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Alan Walker Chief Executive Officer
Allan Watson Chief Financial Officer
William Stimson Ph.D Co-Founder, Chief Scientific Officer and Board Member
Alistair Strachan Ph.D Co-Founder
You’re viewing 4 of 5 executive team members. Get the full list »

ILC Therapeutics Board Members (9)

Name Representing Role Since
Hazel Allen ILC Therapeutics Board Member 000 0000
Kevin Grainger EOS Technology Investment Syndicate Board Member 000 0000
Magnus Nicholson ILC Therapeutics Board Member 000 0000
Peter Bains Self Chairman 000 0000
Richard Morgan ILC Therapeutics Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

ILC Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ILC Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Medical Incubator Japan Venture Capital Minority 000 0000 000000 0
BioCity Accelerator/Incubator 000 0000 000000 0
Eos Advisory Venture Capital Minority 000 0000 000000 0
Scottish Enterprise Venture Capital Minority 000 0000 000000 0
To view ILC Therapeutics’s complete investors history, request access »